Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results

Guardado en:

Detalles Bibliográficos
Publicado en:	Breast Cancer Research vol. 27 (2025), p. 1-16
Autor principal:	Hamilton, Erika P
Otros Autores:	Patel, Manish R, Borges, Virginia F, Meisel, Jane L, Okera, Meena, Alemany, Carlos A, Pluard, Timothy J, Wesolowski, Robert, Sabanathan, Dhanusha, Miller, Kathy D, Conlin, Alison K, McCarthy, Nicole, Shaw, Morena, Tonda, Margaret, Shilkrut, Mark, Lin, Nancy U
Publicado:	Springer Nature B.V.
Materias:	United States > US Plasma Womens health Metastasis Toxicity Cancer therapies Mutation Antitumor activity Laboratories Breast cancer Metastases Estrogens Kinases Estrogen receptors ErbB-2 protein Endocrine therapy Patients Neutropenia Pharmacokinetics Cyclin-dependent kinases Biomarkers Chemotherapy Tumors Cancer
Acceso en línea:	Citation/Abstract Full Text Full Text - PDF
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!